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Abstract
Investigation of the Vpu protein of HIV-1 recently uncovered a novel aspect of the mammalian innate response to
enveloped viruses: retention of progeny virions on the surface of infected cells by the interferon-induced, transmembrane
and GPI-anchored protein BST-2 (CD317; tetherin). BST-2 inhibits diverse families of enveloped viruses, but how it restricts
viral release is unclear. Here, immuno-electron microscopic data indicate that BST-2 is positioned to directly retain nascent
HIV virions on the plasma membrane of infected cells and is incorporated into virions. Virion-incorporation was confirmed
by capture of infectivity using antibody to the ectodomain of BST-2. Consistent with a direct tethering mechanism, we
confirmed that proteolysis releases restricted virions and further show that this removed the ectodomain of BST-2 from the
cell surface. Unexpectedly, enzymatic cleavage of GPI anchors did not release restricted virions, weighing against models in
which individual BST-2 molecules span the virion and host cell membranes. Although the exact molecular topology of
restriction remains unsolved, we suggest that the incorporation of BST-2 into viral envelopes underlies its broad restrictive
activity, whereas its relative exclusion from virions and sites of viral assembly by proteins such as HIV-1 Vpu may provide
viral antagonism of restriction.
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Introduction
The innate defense against viruses includes specific host cell
proteins with intrinsic abilities to restrict viral replication. In some
cases these restriction factors have been linked to classic aspects of
the innate immune response, such as the antiviral state induced by
type I interferons. To replicate in this hostile environment, viruses
encode specific antagonists of restriction factors [1]. Several of the
so-called accessory proteins of primate immunodeficiency viruses
have been recognized as such antagonists. For example, the HIV-1
accessory protein Vpu was long known to enhance the release of
progeny virions from infected cells, potentially by antagonizing an
intrinsic cellular restriction to virion-release [2,3]. The study of this
phenomenon led to the discovery of the antiviral activity of a
protein with no previously known function, BST-2 (also known as
HM1.24 and CD317), now referred to as a ‘‘tetherin’’ based on
its ability to retain nascent virions on the surface of infected
cells [4–6]. BST-2 is an interferon-induced, transmembrane
and GPI-anchored protein that restricts the release of a number
of enveloped viruses including all retroviruses tested as well as
members of the arenavirus (Lassa) and filovirus (Ebola and
Marburg) families [7–10]. However, how BST-2 mediates the
retention of nascent virions is unclear. Viral antagonists of BST-2
include the HIV-1 Vpu, HIV-2 Env, SIV Nef, Ebola glycoprotein,
and KSHV K5 proteins [4,5,11–14]. A common feature of the
antagonism of BST-2 by viral gene products is its removal from
the cell surface, the presumed site of virion-tethering activity.
An unusual membrane topology, localization in cholesterol
enriched membrane microdomains, and homo-dimerization may
each be key to BST-2’s restrictive activity. BST-2 binds the lipid
bilayer twice, via both an N-terminal transmembrane domain and
a C-terminal GPI anchor [8]. This topology leads to the
hypothesis that BST-2 retains virions by directly spanning the
lipid bilayers of the virion and host cell. Many enveloped viruses
including HIV-1 and Ebola bud from cholesterol-enriched
membrane domains in which BST-2 is enriched [15,16]. These
observations lead to the hypothesis that BST-2 is incorporated into
virions as part of the mechanism of restriction. BST-2 forms
disulfide-linked dimers [6]. This observation leads to the hypo-
thesis that the molecular topology of restriction includes dime-
rization between virion- and cell-associated BST-2.
Here, we show that BST-2 is positioned to directly retain virions
on the surface of infected cells and is incorporated into virions. We
confirm that virions retained on the cell surface can be released by
proteolysis, but find that they are not released by cleavage of GPI-
anchors with phosphatidyl inositol specific phospholipase C or by
disulfide reduction with dithiothreitol. Although these findings
leave the precise configuration of the BST-2 molecules that restrict
release unsolved, they support a model in which BST-2 incor-
porates into virions to directly restrict their release from the
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the inhibition of enveloped viruses by BST-2.
Results
BST-2 is present along the plasma membrane in a
punctate distribution and is positioned to directly tether
budding virions
To test the hypothesis that BST-2 is positioned along the plasma
membrane appropriately to directly tether virions, we visualized
the location of the molecule using correlative fluorescence and
electron microscopy. To accomplish this, we labeled the surface of
HeLa cells, which express BST-2 constitutively [5], with a specific
antibody that recognizes the BST-2 ectodomain [17]. This
antibody was secondarily labeled with cadmium selenide/zinc
sulfide nanocrystals (QDots) that are both fluorescent and electron
dense; this property allowed cells labeled identically to be observed
by either light or electron microscopy [18]. The surfaces of cells
labeled for BST-2 were characterized by a punctate staining
pattern when visualized by fluorescence microscopy (Figure 1A
and Figures S1 and S2). This pattern has been noted previously
using routine fluorophores [9,19]. In cells expressing HIV-1, these
puncta appear to contain Gag as well as BST-2 and have been
hypothesized to reflect sites of virion-formation; in uninfected cells
their identity is unclear. Here, in cultures transfected to express the
complete HIV-1 genome including the BST-2 antagonist gene vpu,
some cells were characterized by reduced or absent surface
staining (Figures 1B and S1). In particular, multinucleated cells
resulting from virally induced cell-cell fusion were strikingly low in
surface BST-2 (Figures 1B and S1), consistent with the previously
described reduction in the expression of cell-surface BST-2
induced by Vpu [5]. In contrast, no reduction in surface stain
was seen when cells were transfected to express a vpu-negative
HIV-1 genome; in this case, multinucleated cells resulting from
virally induced cell-cell fusion expressed abundant BST-2 on their
surfaces (Figures 1C and S1). Together, these data indicated that
the QDot-based stain for BST-2 revealed the previously noted
Author Summary
The cellular protein BST-2 prevents newly formed particles
of HIV-1 and other enveloped viruses from escaping the
infected cell by an unclear mechanism. Here, we show that
BST-2 is appropriately positioned to directly retain newly
formed HIV-1 virions on the cell surface and is incorporat-
ed into infectious virions. We suggest that the incorpora-
tion of BST-2 into virions is a key aspect of the protein’s
broadly restrictive activity against enveloped viruses.
Figure 1. Punctate cell surface distribution of BST-2 and surface down-regulation by HIV-1 encoding the Vpu protein. HeLa cells were
left untransfected (A) or transfected with a plasmid expressing the complete wild type HIV-1 genome (B) or with a plasmid expressing an HIV-1
genome lacking vpu (C). The next day, the cells were fixed and stained without permeabilization using an antibody to the BST-2 ectodomain and a
secondary labeling system including streptavidin-conjugated cadmium selenide/zinc sulfide nanocrystals (quantum dots; Qdot 625 nm). Nuclei were
stained with DAPI. Data were acquired as a Z-series of images using an Olympus laser scanning confocal microscope. The images shown are
projections of the entire Z-series for each field. (D) HeLa cells (untransfected) were plated on cover glasses, then fixed in formaldehyde and stained for
surface BST-2 exactly as described above using Qdot 625 nanocrystals. After staining, the cells were further fixed in glutaraldehyde and osmium
tetroxide, followed by conventional embedding and processing for thin-section transmission electron microscopy. Images were obtained using a
JEOL 1200C microscope operated at 80 keV.
doi:10.1371/journal.ppat.1000701.g001
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BST-2 from the cell surface by Vpu as expressed in the context of
the complete viral genome.
To determine the distribution of BST-2 at the ultrastructural
level and in relation to nascent HIV virions, cells stained in an
identical manner to those shown in Figure 1A-C were processed
for transmission electron microscopy. In uninfected cells, BST-2
was found in foci along the plasma membrane (Figures 1D and
S2), which likely correspond to the puncta seen using immuno-
fluorescence. Some of these foci were associated with endocytic
pits, which appeared either coated or uncoated, whereas other
foci were not associated with any apparent structure. In cells
expressing the complete HIV-1 genome including vpu, surface
labeling was often relatively sparse, even in areas of clustered viral
particles (Figure 2A). Such paucity of label is consistent with the
reduced surface expression visualized by fluorescence microscopy.
These wild type viral particles showed both immature (crescentic
electron density along the perimeter of the budding virion), as well
as mature morphology (electron dense cores with occasional
conical shape). In contrast, in cells expressing vpu-negative virus,
BST-2 was readily detectable at the cell surface (Figure 2B).
Furthermore, label was intercalated between the plasma mem-
brane and nascent virions as well as between nascent virions found
in clusters, most of which had a mature morphology. Occasionally,
striking examples of label concentrated at the neck of budding
virions in the case of vpu-negative virus were observed (Figure 2B,
inset). These electron microscopic data indicated that BST-2 is
positioned appropriately to function as a direct tethering factor.
BST-2 is incorporated into infectious HIV-1 viral particles
To determine whether BST-2 is incorporated into virions, we
looked for profiles of budding virions and for profiles of virions
distant from the cell surface. Surprisingly, wild type virions were
not infrequently labeled for BST-2 (Figure 2C and E; see Figure
S3 for control stain). This result is consistent with functional data
indicating that Vpu is not a fully effective antagonist of BST-2 [5],
and it is consistent with the virion-capture and immunoblot
experiments described below. In rare cases, label for BST-2 was
found directly between virions that appeared linked to each other
(Figure 2E). In the case of vpu-negative virus, label was particularly
evident among and between virions caught at a distance from the
plasma membrane (Figure 2D and F). Potential association of such
label with the plasma membrane was excluded by electron
tomography of thick sections; reconstructed three-dimensional
images confirmed the presence of labeled virions that were
unambiguously discontinuous with the plasma membrane (Figure
2G and Video S1). Although substantial variability was observed
in the density of label for BST-2 on and between individual
virions, visual inspection of 38 images yielded 358 virions with 149
virion-associated Qdots in the case of wild type virus and 327
virions with 302 associated Qdots in the case of vpu-negative virus,
indicating a 2.3-fold greater association of label with virions in the
absence of vpu. These immuno-electron microscopic data indicated
that BST-2 is incorporated into virions. The data were also
consistent with a model of viral antagonism in which Vpu
decreases the density of BST-2 at sites of virion assembly and
within virions themselves.
To validate the incorporation of BST-2 into virions, we devised
a bead-based virion-capture assay using the same antibody as was
used above for the morphologic studies. A key feature of this assay
is the virologic readout of infectivity, allowing confirmation that
BST-2 is incorporated into bona fide infectious virions (Figure 3A-
C). Preparations of cell-free virions produced from BST-2-positive
HeLa cells were mixed with antibody to the BST-2 ectodomain, or
with an isotype-matched control antibody, an antibody to CD44,
or an antibody to CD45. The virion-antibody complexes were
then captured on coated magnetic microbeads and used to infect
adherent CD4-positive HeLa indicator cells in an infectious center
assay of HIV-1 infectivity (Figure 3A-C). CD44 is incorporated
into virions and served as a positive control for the capture [20].
CD45 is excluded from virions produced from hematopoietic cells
[21], but here it serves only as a second specificity control, since
CD45 is not known to be expressed on HeLa cells. Strikingly,
antibody to BST-2 captured infectious virus from solution, both in
the case of wild type and vpu-negative genomes. In contrast,
infectious virus (wild type) produced from HEK293T cells, which
do not express BST-2 constitutively [4,5], was not captured by
antibody to BST-2 (Figure 3D). Capture of virions produced from
HeLa cells by antibody to BST-2 was confirmed by measurement
of viral capsid (p24) antigen by ELISA (Figure 3E). The efficiency
of capture as measured by infectivity or p24 ELISA was not
significantly affected by Vpu; this suggests either that Vpu does not
significantly decrease the incorporation of BST-2 into virions
or that both wild type and vpu-negative virions incorporate a
threshold amount of BST-2 sufficient for capture. Immuno-
capture of three independent sets of wild type and vpu-negative
virus preparations confirmed the incorporation of BST-2 into
infectious virions of HIV-1 (Figure 3 and data not shown).
Immunoblot analysis also supported the conclusion that BST-2
is incorporated into virions and further suggested that Vpu inhibits
this (Figure 4, in which virions produced from HeLa cells and
concentrated by centrifugation were analyzed). Remarkably, when
normalized by the volume of the original culture supernates
(Figure 4A, left panel), preparations of wild type virions contained
more BST-2, as well as more p24 capsid protein, than virions
produced by vpu-negative virus. This difference in BST-2 contents
in the volume-normalized samples suggests that the signal was
derived from virions and not merely cellular debris or exosomes; if
the latter were the case, then the volume normalized samples from
cultures expressing wild type virus should have contained less
BST-2, due to Vpu-mediated down-regulation. In contrast, when
the preparations of virions were normalized by their contents of
p24 antigen, BST-2 was essentially only detectable in the absence
of Vpu (Figure 4A and B). The apparent association of BST-2 with
virions and a relative decrease in the content of BST-2 in virions
produced in the presence of Vpu was observed in three inde-
pendent preparations. These observations were robust to filtration
of the virion preparations through 0.22 mM pore size membranes,
suggesting that the detection of BST-2 was not due to the presence
of aggregates of BST-2-containing cellular vesicles and virions
(data not shown). Interestingly, the relatively greater phenotype of
vpu detected in this assay (an apparent 40-fold increase in virion
output) as compared to that detected by measurement of p24 in
unfractionated culture supernatants by ELISA (a 5–8-fold
increase; see Figures 5 and 6) may be due to a reduced fraction
of pelletable p24 when virions are produced in the absence of Vpu
(data not shown). Notably, virions produced in the absence of Vpu
contained, in addition to a triplet of species that migrated with
apparent molecular mass in the range of 27–37 kDa (likely
representing heterogeneously glycosylated BST-2), two bands of
under 20 kDa in apparent mass. These species are less than the
predicted size of unmodified BST-2 (20 kDa), and their identity is
unknown; conceivably, they could represent proteolysis of higher
mass forms. Overall, these immunoblot data, like the results of
immuno-electron microscopy and immuno-capture, support the
conclusion that BST-2 is incorporated into virions. Furthermore,
the immunoblot results suggest that Vpu reduces the virion-incor-
poration of BST-2.
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PLoS Pathogens | www.plospathogens.org 3 March 2010 | Volume 6 | Issue 3 | e1000701Figure 2. Electron microscopic evidence of direct virion tethering and virion-incorporation of BST-2. HeLa cells were transfected to
express the complete HIV-1 genome (wild type; A, C, and E) or a genome lacking vpu (Dvpu; B, D, F, and G), then stained for cell surface BST-2 and
processed for electron microscopy as described in the legend of Figure 1. Panels A-F are images of thin sections obtained using a JEOL 1200C
microscope operated at 80 keV. Panel G is a projection view of a thick section (approximately 250 nm) derived from a tomographic tilt series of
images obtained using an FEI Titan electron microscope operated at 300 keV.
doi:10.1371/journal.ppat.1000701.g002
Direct Retention of Cell Surface Virions by BST-2
PLoS Pathogens | www.plospathogens.org 4 March 2010 | Volume 6 | Issue 3 | e1000701Figure 3. Capture of infectious HIV-1 virions using antibody to BST-2. A. HIV-1 virions were produced by transfection of HeLa cells, which
express endogenous BST-2, either with a plasmid expressing the wild type HIV-1 genome or a genome lacking vpu (Dvpu). Forty-eight hours later,
cell-free culture supernatants were collected, incubated with antibody to CD44, BST-2, CD45, or an IgG2a isotype control, then captured using
magnetic microbeads coated with staphylococcal protein G. Immuno-captured virions were resuspended in the original culture volumes. Virions,
uncaptured or captured using the indicated antibodies, were used to infect CD4-positive HeLa cells containing an LTR-b-galactosidase indicator
construct. Two days later, infectious centers were visualized by incubation with X-gal to generate blue colored foci. Images of individual wells were
acquired using a CCD camera. The wells shown are the result of infection using undiluted preparations, which were each equivalent to 200 ml of the
original, uncaptured cell-free culture supernatants. The uncaptured preparation of wild type virus contained five-fold more HIV-1 p24 capsid antigen
than that of Dvpu, consistent with the restriction of virion-release by endogenous BST-2 and counteraction by Vpu (data not shown). B and C. An
independently prepared set of virions was produced from HeLa cells, subjected to immuno-capture, and infectivity was measured as described for
panel A. Each preparation was serially diluted as shown (‘‘0’’ indicates undiluted sample) and used to infect CD4-positive HeLa cells in duplicate.
Infectious centers were counted using image analysis software; error bars are the actual values of duplicate wells and in some cases are too small to
see. The data shown are representation of three independent experiments. D. Virions (wild type) were produced by transfection of HEK293T cells
lacking endogenous BST-2, subjected to immuno-capture using antibody to BST-2 or an antibody isotype control, and infectivity was measured as in
panels B and C. Data are the averages of duplicate wells; the error bars are too small to see. E. The fraction of the total viral p24 capsid antigen that
was recovered in these immuno-capture experiments was measured using an ELISA. Error bars are the standard deviation of values obtained from
three capture experiments using independent preparations of viruses made from HeLa cells.
doi:10.1371/journal.ppat.1000701.g003
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cells by proteolysis of the BST-2 ectodomain supports a
direct tethering model of restriction
To support further a direct tethering model, we confirmed that
proteolysis with subtilisin releases virions retained on the cell
surface [Figure 5A, in which the black bars indicate the fraction of
the total amount of p24 capsid antigen produced by the culture
that was spontaneously released into the medium after transfection
with wild type or vpu-negative (Dvpu) proviral plasmids; the dark
gray bars indicate the fraction of the total that was further eluted
from the cells with buffer (control) or subtilisin; and the light gray
bars indicate the fraction of the cell-associated p24 that was eluted
with buffer or subtilisin] [22]. The fractional elution of p24 was
greater in the absence of Vpu, consistent with a greater number of
virions initially retained at the cell surface. Notably, these
quantitative data indicated that the total fraction of p24 releasable
from the cells (adding that released spontaneously to that released
by proteolysis with subtilisin; open bars in Figure 5A) is greater in
the case of wild type than Dvpu. The ‘‘non-releasable’’ p24 in the
case of cells expressing vpu-negative virus presumably reflects
virions that have been endocytosed subsequent to restricted release
and are not accessible to proteolysis. We further showed that
proteolysis with subtilisin indeed acts on BST-2; it largely removed
the BST-2 ectodomain from the cell surface as detected by flow
cytometry (Figure 5B), and it degraded the ectodomain in vitro
(Figure 5C). These results are consistent with direct tethering
mediated by BST-2, but they do not discriminate among several
potential topological models of restriction (Figure 5, D-F).
The topology of virion restriction: neither PI-PLC nor DTT
releases nascent virions from the surface of infected cells
The preceding data suggest that the incorporation of BST-2
into viral envelopes and a direct tethering mechanism underlie its
restrictive activity. However, the topology of the BST-2 molecules
that mediate the retention of nascent virions remained unclear.
One hypothesis is that virion-associated BST-2 interacts directly
with cell surface BST-2, potentially via disulfide bonds but alter-
natively via predicted coiled-coil regions in the ectodomain of the
protein (Figure 5D and [4]). Alternatively, one end of BST-2 could
embed in the lipid bilayer of the cell and the other in that of the
virion. Such membrane-spanning models are depicted in Figure
5E and F; notably, BST-2 dimers could span the virion and host
membranes in parallel or anti-parallel orientations.
Here, release of nascent virions was not obtained by incubation
of virus-producing cells with phosphatidyl inositol (PI)-specific
phospholipase C (PLC), which is expected to cleave the GPI-
anchor of BST-2 (Figure 6A). Because BST-2 remains attached to
the cell surface by its transmembrane domain after cleavage of its
GPI anchor (data not shown), PI-PLC activity was validated using
CD55 (decay accelerating factor), which is a typical GPI-anchored
protein (Figure 6D; in which PI-PLC effectively removed CD55
from the cell surface). These data weighed against the membrane-
spanning parallel dimer model of Figure 5F. Incubation of cells
with dithiothreitol (DTT) to reduce disulfide bonds also failed to
release virions (Figure 6B), weighing against a self-interaction
mechanism mediated exclusively by disulfide bonds. Incuba-
tion with PI-PLC followed by DTT (Figure 6C) also failed
to release virions, weighing against an anti-parallel, disulfide
linked, membrane-spanning model (Figure 5E). These data do not
provide direct support for any specific topology of restriction, but
they leave open the possibility that the model shown in Figure
5D is operative via a coiled-coil based interaction between the
ectodomains of virion- and cell-associated BST-2.
Discussion
The interferon induced, GPI-anchored and transmembrane
protein BST-2 restricts the release of enveloped virions from
infected cells by an unclear mechanism. Here, the prototypic
restricted virus, HIV-1, and the prototypic viral antagonist pro-
tein, Vpu, were used to investigate this mechanism. The data
provide key initial support for a model in which BST-2 is a direct
tethering factor that is itself incorporated into infectious virions.
Recent reports have questioned the incorporation of BST-2 into
virions and the co-localization of BST-2 with virion proteins,
leaving a direct tethering model of restriction unsupported [23,24].
An inability to detect BST-2 in virions by immunoblot may be
Figure 4. Virion-associated BST-2 detected by immunoblot. HIV-1 virions were produced by transfection of HeLa cells, which express
endogenous BST-2, either with a plasmid expressing the wild type HIV-1 genome or a genome lacking vpu. Twenty-four hours after transfection,
culture supernatants were centrifuged at 800 g for 8 minutes to remove cellular debris. Virions were concentrated by centrifugation of the clarified
supernatants at 23,000 g for three hours, and then resuspended in SDS- and DTT-containing buffer for quantitation of p24 capsid by ELISA and for
analysis of BST-2 and p24 content by western blot. A. Blots were probed for BST-2. Left lanes were normalized by volume: the wild type sample
contained 85 ng of p24 antigen, whereas the Dvpu sample contained 4 ng of p24 antigen. The greater p24 content of the wild type preparation
reflects the antagonism of BST-2 mediated restriction of virion-release by Vpu. Right lanes were normalized by p24 antigen content (5 ng for each
sample as determined by ELISA). B. Samples analyzed in A were reanalyzed including a dilution series of wild type virions and detection of p24
antigen by immunoblot. Stars indicate lanes with approximately equal content of p24. Western blots for BST-2 were performed as previously
described [19]. Molecular weights are in kilodaltons.
doi:10.1371/journal.ppat.1000701.g004
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more difficult to explain the reported negative data for co-
localization. Here, a combination of morphologic, virologic, and
biochemical approaches provided evidence supporting direct
tethering and virion-incorporation of BST-2.
Evidence that BST-2 is incorporated into virions was provided
by immuno-electron microscopy, immuno-capture of infectious
virions, and routine immunoblot. The immuno-electron micro-
scopic data specifically localized BST-2 as adjacent to virions,
between virions and the plasma membrane, and in rare instances
between virions that were linked to each other. The electron
microscopic data also suggested that the punctate distribution of
BST-2 seen at the cell surface by fluorescence microscopy is only
partly due to the occurrence of the protein in endocytic pits. Many
of the foci seen along the plasma membrane were not associated
with any apparent structure. Intriguingly, these foci could
represent membrane microdomains containing BST-2, such as
cholesterol-enriched lipid rafts, although we cannot exclude that
they reflect antibody-induced lateral aggregation of BST-2 within
the lipid bilayer.
Figure 5. Release of nascent virions and the BST-2 ectodomain by proteolysis of the cell surface with subtilisin; models of direct
tethering. A. HeLa cells were transfected to express the complete HIV-1 genome (WT) or a genome lacking vpu (DVpu). The next day, culture
supernatants were removed to measure the amount of spontaneously released virions (‘‘culture sup’’). The cells were then incubated with buffer
(control) or buffer containing 1 mg/ml subtilisin for 15 minutes at 37C. Proteolysis was stopped by the addition of PMSF to 5 mM; the cells were
pelleted, and the supernatants were removed to measure the amount of virions released (‘‘subtilisin sup’’). The cells were then directly lysed into
Triton-X 100 containing buffer to measure cell-associated viral antigen. The concentrations of HIV-1 p24 capsid antigen were measured in all samples
by ELISA. ‘‘Total’’ indicates the total p24 antigen produced by the culture, i.e., the sum of that released spontaneously, after incubation with buffer or
subtilisin, and cell-associated. ‘‘Cellular total’’ indicates the amount of p24 antigen initially associated with the cells, i.e., the sum of that released by
buffer or subtilisin and cell-associated. ‘‘Culture+subtilisin sup’’ indicates the total amount of p24 antigen releasable from the cell surface, i.e., the sum
of that released spontaneously and after incubation with buffer or subtilisin. Data are the percentages of p24 released; error bars indicate the values
of duplicate measurements. B. HeLa cells were treated with buffer or subtilisin as above; proteolysis was quenched as above; and the cells were
stained with antibody to the BST-2 ectodomain or with an isotype control antibody, and then analyzed by flow cytometry. Lightly shaded curve,
antibody isotype control; unshaded curve, BST-2 after proteolysis of the cell surface using subtilisin; darkly shaded curve, BST-2 on untreated cells. C.
Soluble BST-2 ectodomain (residues 49–180 as described previously [6]) was incubated with the indicated amounts of subtilisin for fifteen minutes
before analysis by SDS-PAGE and detection by immunoblot with antibody specific to the BST-2 ectodomain. D. Model of ectodomain interaction. E.
Model of virion-cell membrane spanning dimer: anti-parallel orientation. F. Model of virion-cell membrane spanning dimer: parallel orientation.
doi:10.1371/journal.ppat.1000701.g005
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capture of infectious virions, and routine immunoblot each
indicated that virions produced in the presence of Vpu are not
devoid of BST-2. However, immunoblot, and to a lesser extent
electron microscopy, suggested that Vpu decreases the amount of
BST-2 in virions. Notably, antibody to the BST-2 ectodomain
captured virions produced in the presence or absence of Vpu
equally well; this may reflect a threshold amount of virion-
associated BST-2 required for immuno-capture that is met by
virions produced in either context. Altogether, these data indicate
the presence of BST-2 in virions. The data also support a relative
but not absolute exclusion of BST-2 from virions by Vpu.
One of two topological models has seemed likely to explain
restriction mediated directly by BST-2: a membrane spanning
Figure 6. Persistence of virion tethering despite cleavage with PI-specific PLC either with or without disulfide reduction. Experiments
were performed as described in the legend of Figure 5, except that rather than subtilisin, specific treatments were used to test models of tethering. A.
Release data using bacterial phosphatidyl inositol-specific phosphoplipase C (PI-PLC; 2.5 U/ml). B. Release data using 5 mM dithiothreitol (DTT) at
37C. C. Release data using PI-PLC followed by DTT. In panels A-C, data are the percentages of p24 released; error bars indicate the values of duplicate
measurements. D. Confirmation of PI-PLC activity using CD55 (decay accelerating factor) as a control protein. HeLa cells were stained with either a
FITC-conjugated isotype control antibody (dotted line), or a FITC conjugated specific antibody to CD55 (dark-outlined open curve and shaded curve),
before analysis by flow cytometry. Cells treated with PI-PLC (2.5 U/ml) are indicated by the dark-outlined open curve, whereas control cells incubated
in buffer only are indicated by the shaded curve.
doi:10.1371/journal.ppat.1000701.g006
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the other in the virion membrane, or a self-interaction model in
which virion-associated and cell-surface-associated BST-2 mole-
cules interact via their ectodomains. Here, we found no direct
support for membrane spanning models; phosphatidyl inositol-
specific phospholipase C (PI-PLC), either with or without disulfide
reduction, failed to release virions retained on the surface of BST-
2-expressing cells. These results weigh against membrane spanning
models involving parallel dimers or anti-parallel dimers held
together by disulfide bonds. A caveat to this interpretation is
that the failure of PI-PLC to release virions could be due to
modification of the GPI anchor of BST-2 such that it is resistant to
this enzyme, a possibility not excluded by the enzyme activity
control herein (release of CD55). As noted above, PI-PLC did not
release BST-2 from the cell surface, consistent with membrane
anchoring by the protein’s transmembrane domain (data not
shown); consequently, we could not validate the activity of PI-PLC
on native BST-2. Similarly, the failure of reduction with DTT to
release virions could be due to an inability of DTT to reach the
key disulfide bond(s) at physiological temperature, for example, if
they are protected within a well-folded structure. Similar attempts
to release virus-like-particles of Ebola retained on the cell surface
by BST-2 with as much as 500 mM DTT were also ineffective
[14]. Recent mutational analyses of cysteine residues within the
BST-2 ectodomain suggest that disulfide-mediated dimerization
is a correlate of the restriction of HIV-1 release, but not of
arenavirus release [25,26]. Notwithstanding these potentially
conflicting findings, exactly how disulfide mediated dimerization
would contribute to restriction, if not by mediating an interaction
between virion- and cell-associated BST-2, is unclear.
A direct restriction mechanism that is not disfavored by any
of the data herein is an ectodomain self-interaction model such
as that shown in Figure 5D, but in which the driving force of
tethering is a coiled-coil based interaction. To test this hypothesis,
the role of the predicted coiled-coil region in the ectodomain needs
to be directly and critically evaluated: are key residues in the
predicted structure required for restriction? Does the putative
interaction responsible for restriction involve two, three, four, or
more a-helices?
Although each of the models of Figure 5 may be too simplistic, a
self-interaction model of restriction is attractive: a single plasma
membrane protein, BST-2, is localized to sites of viral assembly,
incorporates into virions, and dimerizes or forms higher order
multimers or aggregates to restrict release. This direct tethering,
self-interaction model of restriction relies only on the localization
of BST-2 to sites of viral budding and on the incorporation of
BST-2 into virions. Consequently, it can potentially be generalized
to all enveloped viruses that assemble on membrane microdo-
mains that contain BST-2. Conversely, a model of relief of
restriction by removal of BST-2 from the sites of viral assembly
and from virions themselves can potentially be generalized to all
viral proteins that decrease the expression of BST-2 at the plasma
membrane. So far, such proteins include HIV-1 Vpu, HIV-2 Env,
SIV Nef, and KSHV K5 [5,11–13].
Notably, the data herein indicate the presence of BST-2 in
infectious HIV-1 virions that are spontaneously released from
cells, even when the viral antagonist protein Vpu is expressed. The
HeLa cells used for the studies herein express BST-2 endoge-
nously, obviating transient expression methods that may be prone
to artifactual over-expression of BST-2 in individual cells. On the
other hand, whether wild-type virions produced from primary T
cells or produced in vivo contain BST-2 remains to be determined.
The observations herein suggest the possibility that virion-asso-
ciated BST-2 serves functions in addition to tethering nascent
virions. In this regard, we note the potential for virion-associated
BST-2 to interact with ligands, including itself, on immune effector
cells. BST-2 is constitutively expressed, at least in mice, on
plasmacytoid dendritic cells (PDCs), as well as on B cells and
activated T cells in humans [7,27]. Considering the incorporation
of BST-2 into virions and the potential for interaction between
virion- and cell-associated BST-2, we speculate that in addition
to its direct antiviral activity as a tetherin, BST-2 might flag
enveloped viruses for subsequent binding to PDCs and B-cells,
which are antigen-presenting cells, and so stimulate the host
adaptive immune response. Recently, BST-2 was identified as a
ligand for a receptor on PDCs, ILT7, which transduces a signal for
shut-off of interferon production [28]. Based in these findings and
the data herein, we also speculate that virion-associated BST-2
might provide negative feedback to the interferon response. These
mechanisms would place BST-2 at the interface of innate and
adaptive immunity to enveloped viruses.
In conclusion, the data herein advance a direct model of restric-
tion in which BST-2 is found both at the sites of viral assembly
along the plasma membrane and within budding and nasc-
ent virions. While this paper was being finalized, independent
evidence for direct restriction of virus release and virion-incor-
poration of BST-2 was reported [29]. Biochemical data suggested
a parallel dimer configuration. Strikingly, an ‘‘artificial tetherin’’
that lacks primary sequence homology with BST-2, but which
contains its key membrane binding and structural features, showed
antiviral activity, indicating that no cellular cofactors are likely
obligatory for the tethering phenomenon [29]. Directly relevant to
the data herein, a mutant BST-2 lacking a GPI-anchor site was
incorporated into virions but was unable to restrict virion release.
These observations would leave open the role of the GPI-anchor
in restriction, if not as one of the two membrane anchors in virion-
cell membrane spanning models. On the other hand, this study
directly demonstrated a requirement for the coiled-coil ectodo-
main of BST-2 in restriction and showed that a heterologous,
dimeric coiled-coil could provide restrictive activity. These data
can be interpreted to support a coiled-coil based self-interaction
model of restriction. Alternatively, as proposed by the authors, the
coiled-coil structure could be needed for an extended conforma-
tion of the ectodomain, which might facilitate spanning of the
virion- and cell-membranes [29]. While the molecular topology of
the BST-2 molecules that restrict virion release thus remains to be
resolved, the augmentation of BST-2 activity and the inhibition of
viral antagonists such as Vpu likely represent new approaches
to the prevention and treatment of infections due to enveloped
viruses. The development of these approaches depends on under-
standing the regulation of BST-2 during the immune response as
well as on deciphering the structural basis of virion tethering and
of the action of viral proteins that antagonize BST-2 function.
Materials and Methods
Plasmids, antibodies, and reagents
The proviral plasmid pNL4–3 was obtained from the National
Institutes of Health (NIH) AIDS Research & Reference Reagent
Program and contributed by Malcolm Martin [30]. The pNL4-3
mutant DVpu (vpuDEL-1) was provided by Klaus Strebel [31].
The murine monoclonal antibody to BST-2/HM1.24/CD317
and the BST-2 ectodomain protein were gifts from Chugai
Pharmaceutical Co., Kanagawa, Japan [17]. For flow cytometry,
an IgG2a antibody isotype control, a goat, anti-mouse IgG
antibody conjugated to allophycocyanin (APC) and a FITC-
conjugated antibody to CD55/DAF were obtained from BioLe-
gend (San Diego, CA). For immunofluorescence and immuno-
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to biotin was obtained from Jackson ImmunoResearch (West
Grove, PA), and streptavidin-conjugated cadmium selenide/zinc
sulfide nanocrystals (quantum dots; QDot 625) were obtained from
Invitrogen (Carlsbad, CA). Subtilisin was from Sigma-Aldrich. PI-
specific phospholipase-C was from Prozyme, San Leandro, CA or
Sigma-Aldrich.
Cells and transfections
The HeLa cells used in this study were clone P4.R5, which
express both CD4 and CCR5 and were obtained from Ned
Landau; these cells are a derivative of clone P4 and were main-
tained in DMEM plus 10% fetal bovine serum (FBS), penicillin/
streptomycin, and puromycin [32]. HEK293T cells were also
obtained from Ned Landau and were maintained in EMEM
plus 10% FBS and L-glutamine. Cells were transfected using
Lipofectamine2000 (Invitrogen) according to the manufacturer’s
instructions. For the microscopic experiments, cells were trans-
fected in MatTek glass bottom dishes, using 0.8 mg pNL4-3 or
pvpuDel-1. For production of virions, cells were plated in 10 cm
tissue culture dishes and transfected with 16 mg of pNL4-3 or
pvpuDel-1.
Electron and fluorescence microscopy
HeLa P4.R5 cells were plated on coated MatTek glass bottom
dishes and transfected as indicated above. One day after
transfection, the cells were fixed using 3% formaldehyde in PBS
and stained using the murine monoclonal antibody to BST-2/
HM1.24/CD317 (0.05 mg/ml), followed by goat anti-mouse-
biotin (1:100) and streptavidin-QDot 625 (1:100). For fluorescence
microscopy, cells were mounted in anti-fade media containing
DAPI, and image data were obtained using an Olympus laser
scanning confocal microscope. Z-series of two-channel images
were colored, merged and projected using Image J. For trans-
mission electron microscopy, parallel samples were re-fixed in 2%
glutaraldehyde (EM Sciences) in 100 mM sodium cacodylate
buffer (pH 7.4) for 30 min, post-fixed in 1% osmium tetroxide for
30 min, stained in 2% uranyl acetate in water for 1 h, dehydrated
in an ethanol gradient, and embedded in Durcupan ACM (Fluka).
Thin sections were stained with Sato’s lead. Micrographs were
obtained using a JEOL 1200 transmission electron microscope
operated at 80kV. For electron tomography, sections of approx-
imately 250 nm thickness were stained with Sato’s lead and 2%
uranyl acetate. Series of micrographs were collected on a FEI
Titan transmission electron microscope at 300 keV while the
sample was tilted from 260u to +60u in 2u increments. The
micrographs were digitized and aligned using IMOD software
[33]. A transform-based back projection software package was
then used to create the final alignment and back projection
resulting in a three-dimensional volume [34].
Virus production
Virus was produced from either HeLa P4.R5 cells or HEK 293
T cells. Cells (6610
6) were plated in 10 cm tissue culture dishes
and transfected as described above with 16 mg of either pNL4-3 or
pvpuDel-1. Virus-containing culture supernatants were harvested
48 hours later and clarified by centrifugation at 4006g to remove
cellular debris.
Virus immuno-capture
Clarified culture supernatants were incubated with antibodies
as indicated and then complexed to protein G-coated magne-
tic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. Bead-bound virions
were captured using Miltenyi magnetic columns, washed, and
eluted using DMEM plus 10%FBS and penicillin/streptomycin/
puromycin in the same volume as the input supernatant. Viral
protein levels in the eluate were determined using p24 capsid
ELISA (Perkin-Elmer).
Infectivity assay
Infectious center assays of viral infectivity were performed using
HeLaP4.R5 indicator cells as targets. Infected foci were developed
with X-gal, imaged using a CCD camera, and quantified using
image analysis software, as described previously [35].
Flow cytometry
For analysis of surface levels of BST-2, cells were stained before
fixation in phosphate buffered saline (PBS) including sodium azide
and 2% FBS at 4uC using an indirect method to detect BST-2: the
HM1.24 murine monoclonal antibody (0.1 mg/ml) was followed
by a goat anti-mouse IgG conjugated to APC. The gate for BST-2
was set using an antibody isotype control (IgG2a) as the primary
antibody. For measurement of CD55, cells were stained before
fixation either with a FITC-conjugated isotype control or a FITC-
conjugated anti-CD55. Cells were gated by forward and side-
scatter characteristics. Composite data profiles were created using
FlowJo software (Tree Star, Inc.).
Virion-release assays
A p24 antigen capture ELISA (Perkin-Elmer) was used to
determine the concentration of viral capsid protein in culture
supernatants that were first clarified by centrifugation at 400 g as
well as the concentration of capsid protein in detergent lysates
(0.5% Triton-X-100 in PBS) of the adherent cells. The percentage
of p24 capsid secreted into the culture media was determined as
the concentration of p24 antigen in the supernatants divided by
the concentration of p24 antigen in the total culture (supernatant
plus cells) 6100. Additional experimental details are within the
figure legends.
Supporting Information
Figure S1 Distribution of cell surface BST-2 visualized by
Qdot staining and fluorescence microscopy. HeLa cells were
transfected (or not) to express wild type or vpu-negative (Dvpu)
HIV-1, then stained without permeabilization for surface BST-2
using Qdots as described in the legend of Figure 1 and in
the Materials and Methods section. A control in which a non-
specific isotype-matched antibody was used instead of the antibody
to the BST-2 ectodomain is shown in the left-most panel. As
in Figure 1, foci of cells expressing virus are identifiable as
multinucleated, syncytial cells. In the case of wild type, such foci
have reduced or absent stain for surface BST-2. In contrast, the
stain for BST-2 is undiminished in multinucleated cells expressing
vpu-negative virus.
Found at: doi:10.1371/journal.ppat.1000701.s001 (3.20 MB TIF)
Figure S2 Distribution of BST-2 along the plasma membrane of
uninfected cells. HeLa cells were stained for surface BST-2 using
Qdot 625 as the label and processed both for immunofluorescence
(A) and for routine transmission electron microscopy (B) as
described in the legend of Figure 1. Here, the higher magnification
fluorescence image more clearly shows the punctate nature of the
stain, which appears as foci of clustered Qdots along the plasma
membrane by electron microscopy.
Found at: doi:10.1371/journal.ppat.1000701.s002 (2.78 MB TIF)
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type. HeLa cells expressing the wild type viral genome were
processed for immuno-electron microscopy using the Qdot -based
stain as described in the legend of Figure 2 (panels A-F), except
that a non-specific isotype-matched antibody was used instead of
the antibody to the BST-2 ectodomain. Unlike the images of wild-
type virions stained with the anti-BST-2 in Figure 2 panels C and
E, the virions stained with the isotype control are virtually devoid
of label.
Found at: doi:10.1371/journal.ppat.1000701.s003 (5.50 MB TIF)
Video S1 Tomographic reconstructed view of cell surface BST-2
in relation to budding virions. HeLa cells were transfected to
express HIV-1 lacking vpu, then stained with antibody to BST-2
and processed for transmission electron microscopy as described in
Figure 1, except that 250 nm thick sections were cut and a tilt
series of images was obtained for tomography using an FEI Titan
electron microscope operated at 300 keV. The initial segment of
the movie is the raw tilt sequence, which begins with zero degree
tilt, goes to +60 degrees, then to -60 degrees, and ends again at 0
degrees. The tilt sequence transitions into a slice-by-slice back
projected volume, moving through 380 computed slices. The final
segment of the movie is a maximum intensity projection (MIP)
rotated about the Y-axis 720 degrees. The tilt sequence was
acquired using FEI automated acquisition software. The slice-by-
slice back projected volume was processed with the IMOD
software package. MIP visualization and movie production was
done using Visage Imaging’s Amira software package.
Found at: doi:10.1371/journal.ppat.1000701.s004 (7.54 MB
MOV)
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